glp 1 drugs and uti SGLT2i GLP-1 RA therapy in type diabetes and reno-vascular outcomes: a real-world study | Diabetologia Do GLP‑1 receptor agonists (e.g.,

For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%

and (4) were published in English

The burden of mortality attributable to diabetes: Realistic estimates for the year 2000

In REDEFINE 1, which enrolled 3,400 adults without diabetes but with at least one weight-related condition, CagriSema led to an average weight loss of 20.4% at Week 68 , compared to 14.9% with semaglutide, 11.5% with cagrilintide, and 3% with placebo